There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. On December 22, the federal Food and Drug Administration approved Gilead ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid ...

Sunlenca (300 mg tablet and 463.5 mg/1.5 mL injection) [ (lenacapavir)] is a first-in-class, long-acting HIV capsid inhibitor indicated for the treatment of HIV infection, in combination with other ...

The Food and Drug Administration has approved Sunlenca, an injectable therapy to suppress HIV for patients who suffered drug resistance to other regimens. Experts say the new injectable, which works ...

CAPE TOWN, South Africa (AP) — Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. There were no infections ...

Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. Subscribe to read this story ad-free Get unlimited ...

(Reuters) -The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than ...

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...

Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. There were no infections in the young women and girls ...

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23, ...